Serentis initiates recruitment in Phase II dermatitis study

The Phase II, double-blind, vehicle-controlled study will determine the efficacy, safety and tolerability of SRD441 in patients with atopic dermatitis (AD). Results from the Phase II study for SRD441 are expected later in 2009.

The 28-day study in adults with mild or moderate AD is being conducted in 12 sites across Europe and will measure acute efficacy as defined by the Investigators’ Global Assessment, a clinical endpoint commonly used in AD trials.

Robert Tansley, chief medical officer of Serentis, said: “AD is a common condition with an increasing incidence. In a study of over 2,000 patients, a significant majority identified the need for an effective treatment that would give long-term control of their eczema and a much needed improvement to their quality of life. SRD441 represents a new approach with a novel mechanism of action in the treatment and maintenance of AD.”